Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/30/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/17/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
1 | |
| 10/15/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
33 |
| 10/11/24 | DEF 14A | Definitive proxy statements |
|
40 | |
| 10/01/24 | EFFECT | Notice of Effectiveness |
|
1 | |
| 10/01/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
118 | |
| 09/30/24 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
|
25 |
| 09/26/24 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 09/17/24 | UPLOAD | SEC-generated letter |
|
1 | |
| 09/12/24 | EFFECT | Notice of Effectiveness |
|
1 |
